1. Home
  2. Detail

@shahabafridi133: ❤️👀

Sarkar⚜️
Sarkar⚜️
Open In TikTok:
Region: PK
Saturday 14 February 2026 15:46:21 GMT
106
31
12
0

Music

Download

No Watermark .mp4 (0.4MB) Watermark .mp4 (0MB) Music .mp3

Comments

To see more videos from user @shahabafridi133, please go to the Tikwm homepage.

Other Videos

Liv Morgan had some VERY harsh words for Chelsea Green! #SmackDown #WWE
Liv Morgan had some VERY harsh words for Chelsea Green! #SmackDown #WWE
#thelipbar #matteliquidlipstick #makeup #lipcombotutorial
#thelipbar #matteliquidlipstick #makeup #lipcombotutorial
#fouryoupage #memes #وظائف #شغل #بهجت_صابر
#fouryoupage #memes #وظائف #شغل #بهجت_صابر
#مالي_خلق_احط_هاشتاقات🧢😂 #شعب_الصيني_ماله_حل😂🏃‍♀️
#مالي_خلق_احط_هاشتاقات🧢😂 #شعب_الصيني_ماله_حل😂🏃‍♀️
#fypシ゚viral #explorepage✨ #over50club #CityTasteTest #octobermood
#fypシ゚viral #explorepage✨ #over50club #CityTasteTest #octobermood
The drug itself costs less than $10 to make. So why are patients paying thousands? In this conversation, Matthias Tschöp breaks down the economics behind some of today's most talked-about medications. The cost of synthesis, what it actually takes to produce a monthly supply, can be under $10. That's the manufacturing reality. But that number tells only part of the story. The billions spent on research, development, and clinical trials have to come back somehow. And as Matthias Tschöp points out, looking at how well these companies are doing, it's fair to say they've gotten it back. It's a tension worth sitting with. The science is remarkable. The access is another question entirely. Tune into the full conversation, out now on all major streaming platforms. ▶️ youtube.com/@The.Living.Room.Podcast #TheLIVINGRoomPodcast
The drug itself costs less than $10 to make. So why are patients paying thousands? In this conversation, Matthias Tschöp breaks down the economics behind some of today's most talked-about medications. The cost of synthesis, what it actually takes to produce a monthly supply, can be under $10. That's the manufacturing reality. But that number tells only part of the story. The billions spent on research, development, and clinical trials have to come back somehow. And as Matthias Tschöp points out, looking at how well these companies are doing, it's fair to say they've gotten it back. It's a tension worth sitting with. The science is remarkable. The access is another question entirely. Tune into the full conversation, out now on all major streaming platforms. ▶️ youtube.com/@The.Living.Room.Podcast #TheLIVINGRoomPodcast

About

Legal